透析与肾移植患者的总体及部位特异性癌症死亡率
基于澳大利亚和新西兰透析与移植登记系统1980–2014年数据,比较52936例透析患者和16820例移植受者与一般人群的癌症死亡风险。透析患者癌症死亡标化死亡比(SMR)为2.6,移植受者为2.7;透析患者SMR最高的部位为多发性骨髓瘤(30.5)、睾丸癌(17.0)和肾癌(12.5),移植受者为非霍奇金淋巴瘤(10.7)、肾癌(7.8)和黑色素瘤(5.8)。透析患者中61.0%的癌症死亡者存在既往癌症,移植受者中为9.6%;新发癌症SMR在透析患者为1.2,移植受者为2.6。
要点
- 透析和移植患者癌症死亡风险均较一般人群升高逾2.5倍。
- 透析患者癌症死亡主要归因于既往已存在癌症。
- 移植受者癌症死亡风险主要来自新发癌症。
核心结论
- 透析患者和移植受者的癌症死亡风险较一般人群升高超过2.5倍,透析患者主要归因于既往癌症,移植受者主要归因于新发癌症。
研究设计与样本
- 基于澳大利亚和新西兰透析与移植登记系统1980–2014年数据的回顾性队列研究,纳入52936例透析患者和16820例移植受者,分别随访170055人年和128352人年,采用标化死亡比(SMR)比较癌症死亡率。
主要发现
- 透析患者共2739例癌症死亡,移植受者共923例癌症死亡;总体癌症SMR在透析患者为2.6,移植受者为2.7。
- 透析患者SMR最高的部位为多发性骨髓瘤(30.5)、睾丸癌(17.0)和肾癌(12.5)。
- 移植受者SMR最高的部位为非霍奇金淋巴瘤(10.7)、肾癌(7.8)和黑色素瘤(5.8)。
- 透析患者中61.0%的癌症死亡者存在既往癌症,移植受者中为9.6%。
- 新发癌症SMR在透析患者为1.2,移植受者为2.6。
临床怎么用
- 对透析患者应关注既往癌症病史对死亡风险的影响,对移植受者应加强新发癌症的筛查与监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Background Patients with ESRD have a substantially increased cancer risk, but few studies have examined the patterns of cancer mortality along a patient's journey from dialysis to transplantation. METHODS: We identified all Australian patients on dialysis and patients with transplants from 1980 to 2014 from the Australia and New Zealand Dialysis and Transplant Registry. Using standardized mortality ratios (SMRs), we compared cancer mortality among patients on dialysis and patients with transplants versus the general population (overall and by age, sex, year, and site); we also performed a subgroup analysis excluding patients with preexisting cancers. RESULTS: We followed 52,936 patients on dialysis and 16,820 transplant recipients for 170,055 and 128,352 patient-years, respectively. There were 2739 cancer deaths among patients on dialysis and 923 cancer deaths among transplant recipients. Overall, cancer SMRs were 2.6 for patients on dialysis and 2.7 for transplant recipients. For patients on dialysis, SMRs were highest for multiple myeloma (30.5), testicular cancer (17.0), and kidney cancer (12.5); for transplant recipients, SMRs were highest for non-Hodgkin lymphoma (10.7), kidney cancer (7.8), and melanoma (5.8). Some 61.0% of patients on dialysis and 9.6% of transplant recipients who experienced cancer death had preexisting cancer. The SMRs for de novo cancer was 1.2 for patients on dialysis and 2.6 for transplant recipients. CONCLUSIONS: Patients on dialysis and transplant recipients experienced >2.5-fold increased risk of cancer death compared with the general population. This increased risk was largely driven by preexisting cancers in patients on dialysis and de novo cancers in patients with transplants.
引用
- Au EH, Chapman JR, Craig JC, et al. Overall and Site-Specific Cancer Mortality in Patients on Dialysis and after Kidney Transplant. J Am Soc Nephrol. 2019. PMID: 30765426. doi:10.1681/ASN.2018090906
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。